Pharmaceuticals in Thoughts from the Centre

A bold future for life sciences regulation: Predictions 2025

By Karen Taylor, Director, Centre for Health Solutions

Deloitte-uk-life-sciences-predictions-2025-banner

Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.

Continue reading

Posted on 08/11/2018 | 0 Comments

Digital transformation in biopharma: Time for a sea change in strategy

By Mark Steedman, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-boat-navigators-through-lens

Deloitte recently conducted a survey with the MIT Sloan Management Review to assess the digital maturity of companies across a wide variety of industries.1 Our colleagues in the US Center for Health Solutions analysed the responses from biopharma companies and published them in a separate report - Survey finds biopharma companies lag in digital transformation: It is time for a sea change in strategy.2 Headlining the report is the finding that only 20 per cent of biopharma respondents think their companies are digitally mature, compared to 30 per cent across all industries.3 

Continue reading

Posted on 26/10/2018 | 0 Comments

Fighting the opioid crisis – a UK perspective

By Matthew Thaxter

Tablets

By now, it is likely that most people have heard about the ongoing opioid crisis in the US, as barely a day goes by without some form of media coverage. Recent stories have also emerged of a significant upward trend in opioid prescriptions in the UK. This blog explores some of the drivers behind the US crisis, and how likely we are to see a similar epidemic here in the UK.

Continue reading

Posted on 05/10/2018 | 0 Comments

World Alzheimer’s Day

By Mark Steedman, PhD. Manager Centre for Health Solutions

Alzhimer

In the late 1970s, Earth, Wind & Fire released one of their biggest hits – September – with an opening line that has become an internet meme and is widely recognised around the world.

“Do you remember the 21st night of September?”

Continue reading

Posted on 21/09/2018 | 0 Comments

Turbo charge your drug development: How pharma companies should use emerging technologies

by Dr Francesca Properzi PhD

Drug

 We are delighted to use this week’s blog to introduce the Centre’s new Research Manager, Francesca Properzi, who joined the team last week. Here is Francesca’s take on the way emerging technologies can improve pharma R&D.

R&D management in the pharmaceutical industry is facing unprecedented challenges. While the availability of new high-impact technologies has the potential to help reshape research and clinical development, our latest report from our Measuring the return from pharmaceutical innovation series, A new future for R&D?, shows the costs of drug development for 12 large cap pharma companies has increased sharply over the past eight years by nearly 50 per cent, totalling just under $2 billion per drug.  Although a number of therapies are still expected to achieve blockbuster status, lower projected R&D returns are decreasing sharply from a once double digit high to an average of slightly over three per cent. This exceedingly low internal rate of return (IRR), is mostly due to companies paying the price of lower post-approval sales and increased R&D costs.   

Continue reading

Posted on 14/09/2018 | 0 Comments

Digital R&D: Four ways to maximise patient engagement in clinical trials

by Dawn Anderson, Managing Director, Deloitte Consulting LLP

Testtubes

The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials.

Continue reading

Posted on 17/08/2018 | 0 Comments

Blockchain: Picking the right links for the Life Science and Health Care industries

by Amen Sanghera, Analyst, UK Deloitte Centre for Health Solutions and Rui Zhou, Consultant, Deloitte Canada

Chain

Blockchain is increasingly touted as the technology that could transform many of the challenges facing healthcare and life sciences; whether it is providing secure and interoperable electronic health records (EHR), increasing the integrity of clinical trials data or improving the transparency of life science’s supply chain operations. While, the technology itself is not revolutionary, using it in the right situation, especially where trust, consensus or immutability are essential to the operations of the Life Science and Health care industries, could be transformational.

Continue reading

Posted on 27/07/2018 | 0 Comments

R&D leaders roundtable: the key takeaways to help address pharma’s R&D productivity challenge

by Colin Terry, Partner, Deloitte Consulting

Future-of-rd

Following the launch of our eighth annual report ‘A new future for R&D? Measuring the return from pharmaceutical innovation 2017’, we hosted a peer-to-peer discussion on how R&D leaders can address R&D performance trends. The roundtable stimulated many insightful discussions among the senior R&D executives in attendance, and below are some of the key takeaways that resonated most with me.

Continue reading

Posted on 27/07/2018 | 0 Comments

Five barriers that could keep biosimilar manufacturers from cracking the US market

by James Forsyth, Director, Deloitte MCS Limited, and Cameron McClearn, Principal, Deloitte Consulting LLP

Writing

This week’s blog by James Forsyth (Director Deloitte MCS) and Cameron Mclearn (Principle Deloitte Consulting US) featured on the US Center for Health Solutions blog, A view from the Center, earlier this week.1 The article explores the challenges that are keeping biosimilar manufacturers from gaining more traction in the US market.

Continue reading

Posted on 29/06/2018 | 0 Comments

Emerging technologies can boost performance in clinical trials

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Athletes

This week’s blog by Greg Reh, Deloitte’s Global Life Sciences Leader first featured on the US Center for Health Solutions blog, A view from the Center.i In it Greg explores how emerging technologies can improve enrolment in, remove barriers of participation and increase drug adherence in pharma clinical trials.

Continue reading

Posted on 01/06/2018 | 0 Comments